nature portfolio

Corresponding author(s):	Justin Taylor
Last updated by author(s):	Sep 7, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

S:	ta	ti	ist	ti	CS

For	all statistical ar	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a	Confirmed					
	The exact	ct sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	A stateme	ment on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
	The statis Only comm	e statistical test(s) used AND whether they are one- or two-sided or common tests should be described solely by name; describe more complex techniques in the Methods section.				
	A descript	A description of all covariates tested				
	A descript	🔀 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full desc	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.					
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated						
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.						
Software and code						
Policy information about <u>availability of computer code</u>						
Da	nta collection	No software was used.				
Da	nta analysis	No software was used.				
	For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and					

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data will be made available by contacting the corresponding authors.

Human rese	arch parti	cipants			
Policy information about studies involving human research participants and Sex and Gender in Research.					
Reporting on sex and gender		Sex and gender analysis was not performed due to the disease equally affecting both sexes.			
Population characteristics		Details on the four patients included are described in the manuscript.			
Recruitment		Sequential patients were recruited from the clinic.			
Ethics oversight		University of Miami IRB			
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.			
Field-spe	ecific re	porting			
Please select the o	ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
\times Life sciences	B	ehavioural & social sciences			
For a reference copy of	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scier	nces sti	udy design			
All studies must dis	sclose on these	points even when the disclosure is negative.			
Sample size	No sample size calculation was performed. These were rare patients so all patients available were included.				
Data exclusions	No data were excluded				
Replication	Experiments were replicated in at least triplicates. All experimental findings were replicated.				
Randomization	Randomization was not performed				
Blinding	Blinding was not possible.				
Reporting for specific materials, systems and methods We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.					
Matariala P. avraginantal avatana					
	Materials & experimental systems n/a Involved in the study Methods n/a Involved in the study				
		Flow cytometry			
	Palaeontology and archaeology MRI-based neuroimaging Animals and other organisms				
Clinical data					
Dual use research of concern					
Antibodica					

Antibodies

antibodies against Cyclin D1 (BD Biosciences, San Jose, CA); XPO1 and p53 (Santa Cruz Biotechnology, Dallas, TX); and MCL-1 and p65 (Cell Signaling Technologies, Danvers, MA), all used at 1:1000 dilution in 1% BSA. β-actin (Sigma Aldrich) was used at 1:10,000. Antibodies used Validation

These were purchased from companies with reputable validation techniques.

Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research

RPMI-8226 and U266-B1 cell lines were purchased from ATCC (Manassas, VA). OPM2 and KMS12BM cell lines were a kind gift Cell line source(s) from Dr. Leif Bergsagel from Mayo Clinic.

Authentication Cell lines were authenticated by STR sequencing.

N/A

Cell lines were tested for mycoplasma with the MycoAlert mycoplasma detection kit (Catalog # LT07-218, Lonza, Morristown, Mycoplasma contamination

Commonly misidentified lines (See ICLAC register)

Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Laboratory animals Mice, NSG-SGM3, Female, Age 3 months

Wild animals N/A

Sex and gender analysis was not performed due to the disease equally affecting both sexes. Reporting on sex

Field-collected samples N/A

Ethics oversight University of Miami has full AAALAC accreditation; complies with Federal laws and regulations including the Animal Welfare Act

(AWA) regulations overseen by the USDA, PHS Policy on Humane Care and Use of Laboratory Animals administered

by the NIH, Office of Laboratory Animal Welfare (OLAW); and has an assurance letter on file with the DHHS (assurance #A3224-01).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about <u>clinical studies</u>

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration

Study protocol Protocol is on file with IRB

Data collection Data were collected by retrospective chart review

Outcomes were not on a clinical trial and just for the four patients included. Outcomes